Stay updated with breaking news from Data Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mansfield, MA (PRWEB) May 26, 2021 -- Mansfield, MA, May 26, 2021 — eClinical Solutions LLC, a global provider of cloud-based enterprise software and
Clark Freight Lines, with 180 trucks, used to routinely file lots of DataQs RDRs (Requests for Data Review) but met with little success, said Vice President Danny Schnautz. He gave the example of a violation for an air leak that wasn’t in fact a safety violation. “What we found out was it made the police department really mad,” he said, particularly when the challenge was filed with little in the way of hard evidence. “Now we don’t dispute it unless we have real proof.” Depending on what the violation is, and how attentive to the allegation any individual operator was duri...
(** B P) War economy flourishing behind the walls of Houthis detention centers Among the group of detainees who were released by paying money to Houthi mediators or supervisors spoke with Almasdar Online, Al-Sabri was the only one who agreed to disclose his name. The others asked to remain anonymous to protect themselves and their relatives who still live in Houthi-controlled areas from retribution. Other former detainees categorically refused to tell their stories for this report, out of fear of what Houthi authorities would do if they found out. A systematic campaign of random arrests Houth...
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued Immutep’s Collaboration and Exclusive License with GSK Remains in Place January 21, 2021 17:40 ET | Source: Immutep Limited Immutep Limited Sydney, AUSTRALIA Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase II clinica...
Immutep: GlaxoSmithKline Discontinues Phase II Study On Ulcerative Colitis LONDON (dpa-AFX) - Immutep Limited (IMMP) said that its licensing partner GlaxoSmithKline plc. (GSK.L, GSK) has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, in patients with active ulcerative colitis. GlaxoSmithKline stopped the trial based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial's Data Review Committee. However, GSK is conducting further reporting, assessment and analyses of th...